Last reviewed · How we verify

agalsidase beta (GZ419828) — Competitive Intelligence Brief

agalsidase beta (GZ419828) (agalsidase beta (GZ419828)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic disease / Lysosomal storage disorder.

marketed Enzyme replacement therapy Alpha-galactosidase A Rare genetic disease / Lysosomal storage disorder Small molecule Live · refreshed every 30 min

Target snapshot

agalsidase beta (GZ419828) (agalsidase beta (GZ419828)) — Sanofi. Agalsidase beta is a recombinant human alpha-galactosidase A enzyme that breaks down globotriaosylceramide (Gb3) accumulation in cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
agalsidase beta (GZ419828) TARGET agalsidase beta (GZ419828) Sanofi marketed Enzyme replacement therapy Alpha-galactosidase A
Galafold MIGALASTAT Amicus Therap Us marketed Alpha-galactosidase A 2018-01-01
Pegvaliase-Pqpz Pegvaliase-Pqpz University of Missouri-Columbia marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme)
ALGLUCOSIDASE ALFA (MYOZYME) ALGLUCOSIDASE ALFA (MYOZYME) Genzyme, a Sanofi Company marketed Enzyme replacement therapy Acid alpha-glucosidase (GAA)
creon 35.000 Ph.U (R) creon 35.000 Ph.U (R) Hospital Clinico Universitario de Santiago marketed Pancreatic enzyme replacement therapy
Cerezyme® / Imiglucerase Cerezyme® / Imiglucerase Sanofi marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase)
Replagal (agalsidase alfa) Replagal (agalsidase alfa) Shire marketed Enzyme replacement therapy α-galactosidase A (GLA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). agalsidase beta (GZ419828) — Competitive Intelligence Brief. https://druglandscape.com/ci/agalsidase-beta-gz419828. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: